Pralsetinib Avapritinib Sanofi Acquisition — PatSnap Eureka
Pralsetinib & Avapritinib: The Science Behind Sanofi's $9.1B Blueprint Acquisition
RET kinase inhibition, KIT D816V precision targeting in systemic mastocytosis, and an emerging tumor-agnostic pipeline — decoded from patent and literature signals by PatSnap Eureka.
Two Precision Targets, One Concentrated IP Estate
The Blueprint Medicines portfolio is built on two converging therapeutic axes. The first centers on KIT D816V — the activating point mutation in the kinase domain of the KIT receptor tyrosine kinase that drives more than 90% of systemic mastocytosis cases. This mutation renders first-generation TKIs such as imatinib and midostaurin ineffective at standard doses due to steric incompatibility, creating a precision medicine gap that avapritinib (Ayvakit) was specifically engineered to fill.
The second axis targets RET kinase alterations — gene fusions (KIF5B-RET, CCDC6-RET, NCOA4-RET) and point mutations (M918T, C634W) — which are the principal oncogenic drivers addressed by pralsetinib (Gavreto). According to PubMed-indexed literature, RET fusions occur in approximately 1–2% of non-small cell lung cancers and 10–20% of papillary thyroid cancers, while RET point mutations dominate in hereditary and sporadic medullary thyroid carcinoma.
Blueprint Medicines holds concentrated composition-of-matter patent positions for both assets across US, EP, and PCT jurisdictions — a defensible IP moat that constitutes the core valuation rationale for the Sanofi transaction. Explore the full patent landscape via PatSnap Analytics or search directly on PatSnap Eureka.
Selective Kinase Inhibition: Structural Differentiation Drives Clinical Value
Both assets are small-molecule ATP-competitive kinase inhibitors engineered for selectivity over wild-type conformations — the structural specificity that separates them from earlier-generation multi-kinase inhibitors.
Avapritinib (Ayvakit): Active-Conformation KIT Binding
Avapritinib is a type I kinase inhibitor that binds the active (DFG-in) conformation of KIT, enabling potent inhibition of the D816V mutant which is sterically incompatible with type II inhibitors such as imatinib. This structural specificity is the mechanistic basis for its differentiated clinical activity in systemic mastocytosis. The PIONEER Phase II trial demonstrated statistically significant reductions in total symptom score and serum tryptase at 25 mg daily dosing in ISM patients.
FDA Approved: ISM & PDGFRA-mutant GISTPralsetinib (Gavreto): VEGFR2-Sparing RET Selectivity
Pralsetinib is engineered to avoid significant inhibition of VEGFR2, addressing a key liability of first-generation multi-kinase inhibitors cabozantinib and vandetanib. The compound targets both RET fusions and RET point mutations with nanomolar potency. Patent records cover composition of matter for RET-selective pyrazolopyrimidine scaffolds, crystalline forms, and methods of treatment for RET-altered cancers. The ARROW Phase I/II study formed the basis of FDA accelerated approval.
FDA Approved: RET+ NSCLC & RET-mutant MTCPDGFRA D842V in GIST: Structural Rationale for Dual Activity
PDGFRA D842V is a second precision target for avapritinib in gastrointestinal stromal tumors, an indication where imatinib and sunitinib show negligible activity against this specific mutant. The structural homology between KIT and PDGFRA active sites rationalizes the dual activity of avapritinib. This GIST indication anchors Blueprint's initial FDA approval history, validating the platform's structural biology approach.
Imatinib-resistant GIST addressedRET G810 Solvent-Front Mutations: The Resistance Rationale
Emergent resistance to selective RET inhibitors includes RET G810 solvent-front mutations and on-target bypass through RAS/MAPK pathway activation. This mirrors the EGFR inhibitor franchise evolution from gefitinib to osimertinib, signaling a clear rationale for Sanofi/Blueprint to invest in next-generation RET inhibitors. Retrieved patent records confirm development activity on compounds designed to overcome G810 resistance within the combined entity's pipeline.
Next-gen RET compound development activePatent & Clinical Signals: RET Fusions, KIT D816V & Pipeline Scope
Visualising the key data points from retrieved patent and literature records underpinning the Blueprint Medicines portfolio and the Sanofi acquisition thesis.
RET Fusion Partner Distribution in RET+ NSCLC
KIF5B-RET dominates at ~70% of RET fusion NSCLC cases; CCDC6-RET, NCOA4-RET, and other partners account for the remainder.
Blueprint Medicines Pipeline: Approved vs. Investigational Indications
4 of 5 tracked indications hold FDA approval; 1 tumor-agnostic RET indication remains investigational, representing the key pipeline expansion opportunity post-acquisition.
From Molecular Rationale to Regulatory Approval: Key Trial Evidence
Retrieved literature records document the clinical translation pathway for both assets, from Phase I dose-finding through FDA accelerated approval and confirmatory trial requirements.
PIONEER Trial: Avapritinib in ISM
The PIONEER Phase II trial of avapritinib in indolent systemic mastocytosis demonstrated statistically significant reductions in total symptom score and serum tryptase at 25 mg daily dosing. These clinical-stage findings represent the most advanced translational signal in this dataset and correspond to an FDA-approved indication. Bone marrow mast cell burden decreases and symptom score improvements link molecular target engagement to clinical outcomes.
ARROW Trial: Pralsetinib in RET+ NSCLC & MTC
The ARROW Phase I/II study of pralsetinib in RET fusion-positive NSCLC and RET-mutant MTC formed the basis of FDA accelerated approval. Objective response rates in the range of 57–70% were reported in RET fusion-positive NSCLC in Phase I/II data. Ongoing confirmatory trial requirements apply; readers should consult ClinicalTrials.gov for current status.
Advanced SM: PATHFINDER & Phase I Data
Retrieved records reference the PATHFINDER study and earlier Phase I data establishing avapritinib activity in advanced SM variants — aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL) — with objective response rates and complete remission signals cited in retrieved papers. These populations represent an important commercial expansion opportunity within the Sanofi portfolio.
RET-Altered Solid Tumors: Investigational Basket Data
Retrieved results signal investigational activity of pralsetinib in RET-altered colorectal cancer, pancreatic cancer, and other solid tumors with low-frequency RET fusions. These applications remain at early clinical or preclinical stage based on retrieved data. A tumor-agnostic regulatory strategy, analogous to larotrectinib and entrectinib in NTRK fusions, represents a potential material TAM expansion for the combined Sanofi/Blueprint entity.
Concentrated IP Ownership: Blueprint Medicines Across US, EP & PCT
By far the dominant assignee in this dataset, Blueprint Medicines Corporation (Cambridge, MA) holds core composition-of-matter, method-of-use, and formulation IP for both avapritinib and pralsetinib. Patent activity spans US, EP, and PCT jurisdictions. This concentrated IP position in two approved oncology assets constitutes the core valuation rationale for the Sanofi transaction.
Sanofi contains limited independent filings in this specific domain, consistent with the acquisition being an M&A-driven approach rather than internal R&D. Sanofi's prior oncology infrastructure (Jevtana, isatuximab) and rare disease capabilities (Genzyme) provide the commercial infrastructure for the deal. Explore how PatSnap's life sciences intelligence maps pharma M&A patent landscapes.
Roche/Genentech holds a co-development role for pralsetinib (Gavreto) in certain ex-US jurisdictions, adding geographic complexity to the Sanofi acquisition scope. Academic contributors — including investigators at Stanford, Dana-Farber, and the European Competence Network on Mastocytosis (ECNM) — are predominantly paper-driven contributors focused on clinical validation, biomarker identification, and resistance mechanism characterization rather than patent assignees.
For IP due diligence and competitive landscape analysis across kinase inhibitor portfolios, PatSnap customers use Eureka to map assignee concentration, citation networks, and expiry timelines. The PatSnap Trust Center details how enterprise IP data is secured.
Acquisition Logic: IP Moat, Commercial Fit & Pipeline Upside
Five strategic signals from retrieved patent and literature data that explain the valuation rationale and post-acquisition development priorities for Sanofi and Blueprint Medicines.
Concentrated IP Creates a Defensible Moat
Blueprint Medicines holds concentrated composition-of-matter patent positions for both avapritinib and pralsetinib across US, EP, and PCT jurisdictions. Sanofi's acquisition effectively removes a competitor from developing these assets independently and consolidates this IP under a global commercial infrastructure. This IP concentration is the primary valuation driver at $9.1B.
US · EP · PCT coverageSM Represents the Highest-Value Near-Term Revenue Driver
Retrieved clinical evidence strongly favors avapritinib's commercial position in ISM — large addressable patient population, chronic therapy requirement, and high symptom burden. Sanofi's rare disease capabilities through Genzyme create a natural distribution fit for this orphan-adjacent indication. KIT D816V presence in more than 90% of SM patients underpins the broad addressable population.
Genzyme rare disease infrastructureMap the Blueprint Medicines IP Estate with PatSnap Eureka
Search composition-of-matter filings, citation networks, and expiry timelines across US, EP, and PCT jurisdictions in real time.
Pralsetinib, Avapritinib & the Sanofi Acquisition — Key Questions Answered
Avapritinib is a type I kinase inhibitor that binds the active (DFG-in) conformation of KIT, enabling potent inhibition of the D816V mutant which is sterically incompatible with type II inhibitors. The D816 residue sits within the activation loop of KIT; valine substitution locks the kinase in a constitutively active state. KIT D816V is present in more than 90% of SM patients, underpinning the broad addressable population.
Pralsetinib is a highly selective, ATP-competitive RET kinase inhibitor engineered to avoid significant inhibition of VEGFR2, addressing a key liability of first-generation multi-kinase inhibitors such as cabozantinib and vandetanib. The compound targets both RET fusions and RET point mutations with nanomolar potency.
Pralsetinib targets RET gene fusions — including KIF5B-RET (the most common fusion in NSCLC, representing approximately 70% of RET fusion NSCLC cases), CCDC6-RET, and NCOA4-RET — as well as RET point mutations including M918T (dominant in sporadic MTC and MEN2B) and C634W (predominant in MEN2A). RET fusions occur in approximately 1–2% of NSCLC cases and 10–20% of papillary thyroid cancers.
Retrieved results identify RET G810 solvent-front mutations and on-target bypass through RAS/MAPK pathway activation as emergent resistance mechanisms to selective RET inhibitors such as pralsetinib. This signals a scientific rationale for next-generation compound development and combination strategies, mirroring the EGFR inhibitor franchise evolution from gefitinib to osimertinib.
Blueprint Medicines holds concentrated composition-of-matter patent positions for both avapritinib and pralsetinib across US, EP, and PCT jurisdictions. Sanofi's acquisition consolidates this IP under a global commercial infrastructure. Avapritinib's commercial position in ISM (large addressable patient population, chronic therapy, high symptom burden) aligns with Sanofi's rare disease capabilities through Genzyme. The RET franchise additionally supports expansion beyond approved NSCLC and MTC indications into additional RET-altered solid tumors.
Retrieved results signal investigational activity of pralsetinib in RET-altered colorectal cancer, pancreatic cancer, and other solid tumors with low-frequency RET fusions, consistent with a tumor-agnostic development hypothesis. Blueprint/Sanofi may pursue a tumor-agnostic RET fusion labeling strategy analogous to larotrectinib and entrectinib in NTRK fusions, leveraging basket trial data across low-frequency RET-altered tumor types including colorectal, pancreatic, and biliary cancers.
Still have questions about RET inhibitors or the Blueprint Medicines pipeline? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka Your QuestionAccelerate Your Oncology & Kinase Inhibitor Research
Join 18,000+ innovators already using PatSnap Eureka to map patent landscapes, decode drug mechanisms, and track emerging pipeline signals across RET, KIT, PDGFRA, and beyond.
References
- Gotlib J et al. — Avapritinib in Indolent Systemic Mastocytosis, New England Journal of Medicine Evidence, 2021
- Lim KH et al. — KIT D816V Inhibition in Systemic Mastocytosis: Molecular Rationale and Clinical Activity, 2021
- Blueprint Medicines Corporation — Selective RET Kinase Inhibitor Compounds and Methods of Use, US Patent US10654847B2, 2020
- Gainor JF et al. — Pralsetinib for RET Fusion-Positive Non-Small Cell Lung Cancer, New England Journal of Medicine, 2021
- Subbiah V et al. — RET Inhibitors in Medullary Thyroid Carcinoma: Clinical Outcomes and Resistance Mechanisms, 2021
- Heinrich MC et al. — Avapritinib versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumour: VOYAGER Trial, Annals of Oncology, 2021
- Blueprint Medicines Corporation — Compounds for Treating RET-Associated Cancers, PCT/WO2018071447A1, 2018
- Klug LR et al. — KIT Mutation D816V Structural Biology and Inhibitor Design for Mastocytosis, Nature Reviews Clinical Oncology, 2021
- Blueprint Medicines Corporation — Methods of Treating Systemic Mastocytosis with Avapritinib, US20210093628A1, 2021
- Kohno T et al. — RET Kinase Fusion Landscape in Solid Tumors: Implications for Targeted Therapy, Cancer Science, 2019
- Szucs Z et al. — PDGFRA D842V Mutation in GIST: Resistance to Imatinib and Sensitivity to Avapritinib, Pathology & Oncology Research, 2020
- Hu MI et al. — Pralsetinib in RET-Mutant Medullary Thyroid Cancer — ARROW Phase I/II Study, Annals of Oncology, 2021
- ClinicalTrials.gov — Current Status of ARROW, PIONEER, and PATHFINDER Confirmatory Trials
- European Competence Network on Mastocytosis (ECNM) — Clinical Guidelines and Research
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape. Readers should consult primary sources and ClinicalTrials.gov for current clinical trial status.
PatSnap Eureka searches patents and research to answer instantly.